Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
EMBC · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortEmbecta Corp. is profitable.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 22.4% | 91/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.8% | 55/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 22.7% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.41× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 4.15× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.99 | 23/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 16.9% | 88/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.91× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 4.4% | 95/100 |
| Operating margin volatility | 10.5% | 14/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -1.5% | 8/100 |
|---|---|---|
| EPS growth, 3-year average | -25.3% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,165 | 1,130 | 1,121 | 1,123 | 1,080 |
| Cost of revenue | 365 | 355 | 371 | 388 | 404 |
| Gross profit | 800 | 775 | 750 | 735 | 677 |
| Research & development | 63 | 67 | 85 | 79 | 37 |
| Selling, general & admin | 240 | 295 | 341 | 365 | 332 |
| Operating income | 492 | 310 | 222 | 167 | 242 |
| Pre-tax income | 495 | 257 | 106 | 44 | 136 |
| Income tax | 80 | 33 | 35 | (34) | 41 |
| Net income | 415 | 224 | 70 | 78 | 95 |
| Diluted EPS | $7.28 | $3.89 | $1.22 | $1.34 | $1.62 |
| Diluted shares (millions) | 57 | 57 | 58 | 58 | 59 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
1.99 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 7, 2026